Andrew Witty: The acceptable face of big pharma

BMJ (Online)

Volumn 346, Issue 7898, 2013, Pages

  Coombes, Rebecca ^a  

^a BMJ ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; PAROXETINE; ZANAMIVIR;

CAREER; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; NOTE; PATENT; PRIORITY JOURNAL; PROFIT; PUBLIC RELATIONS;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; GREAT BRITAIN; MARKETING; ORGANIZATIONAL CULTURE; PUBLIC RELATIONS;

EID: 84874848287     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1458     Document Type: Note

References (2)

1. Kmietowicz Z. GSK backs campaign for disclosure of trial data. BMJ 2013;346:f819
2. Jack A. Mea culpa: are multibillion dollar fines forcing drug companies to clean up their act? BMJ 2012;345:e4865.